8-K Announcements
6Material company update
May 26, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
Apr 10, 2026·SEC
Leap Therapeutics, Inc.(LPTX)Earnings, Financials & Key Ratios
LPTX•NASDAQ
$0.77
11.0× P/E·Price updated Jun 20, 2026
AboutLeap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Show more
- Revenue$0
- EBITDA-$37M+47.8%
- Net Income$5M+107.1%
- EPS (Diluted)0.07+103.8%
- ROE5.11%+103.6%
LPTX Price & Volume
Leap Therapeutics, Inc. (LPTX) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Liquidity Runway
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity shortfall
Key Thesis Takeaways
- Leap Therapeutics faces a precarious outlook as its reliance on high-cost clinical development continues to erode its capital base without a corresponding commercial revenue stream.
- The company's reliance on external financing to sustain operations, evidenced by a $539.7M accumulated deficit, suggests significant long-term dilution risks for shareholders.
- Investors should monitor the firm's ability to reach critical clinical milestones before its remaining $6.7M cash position is fully exhausted.
Verdict Logic
the company's cash position has deteriorated to $6.7M as of 2026Q1, which appears insufficient to support late-stage clinical development without further dilutive financing.
LPTX Growth Metrics
Leap Therapeutics, Inc. (LPTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-10.68%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM39.4%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM98.82%
Return on Capital
10 Years-90.07%
5 Years-90.56%
3 Years-112.05%
Last Year-37.73%
Peers Comparison
Key metrics vs top competitors for Leap Therapeutics, Inc. (LPTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.77 | $64.53M | 10.99 | — | — | 5.11% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $3.50 | $145.75M | -1029.41 | 10.37% | 52.16% | — | — | |
| $53.52 | $8.19B | 19.32 | 87.32% | 65.95% | 87.36% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $74.90 | $1.46B | -7.70 | -43.89% | -284.18% | -87% | — |
Compare LPTX vs Peers
Leap Therapeutics, Inc. (LPTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LPTX SEC Filings & Documents
Leap Therapeutics, Inc. (LPTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when LPTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LPTX Frequently Asked Questions
Leap Therapeutics, Inc. (LPTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Leap Therapeutics, Inc.'s revenue?
Leap Therapeutics, Inc. (LPTX) reported $0.2M in revenue for fiscal year 2025.
Is LPTX profitable?
Leap Therapeutics, Inc. (LPTX) reported a net loss of $56.9M for fiscal year 2025.
Dividend & Returns
What is LPTX's return on equity?
Leap Therapeutics, Inc. (LPTX) has a return on equity (ROE) of 5.1%. This is below average, suggesting room for improvement.
What is Leap Therapeutics, Inc.'s free cash flow?
Leap Therapeutics, Inc. (LPTX) had negative free cash flow of $79.6M in fiscal year 2025, likely due to heavy capital investments.